Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 131 publications
Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.
Journal: Gynecologic oncology reports
Published: July 03, 2026
Mirvetuximab Soravtansine Exposure and Incidence of Cataract Surgery.
Journal: JAMA network open
Published: May 21, 2026
Homozygous Loss of Recombination Repair Genes and Poly ADP-Ribose Polymerase Inhibitor Benefit for Patients With Ovarian Cancer.
Journal: JCO precision oncology
Published: May 14, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 08, 2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Journal: Gynecologic oncology
Published: March 19, 2026
MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Journal: Gynecologic oncology
Published: February 15, 2026
A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).
Journal: Frontiers in oncology
Published: February 11, 2026
Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.
Journal: JAMA oncology
Published: January 02, 2026
Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer.
Journal: Current opinion in obstetrics & gynecology
Published: December 29, 2025
Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates.
Journal: Scientific reports
Published: December 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Journal: Research square
Published: November 19, 2025
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma.
Journal: medRxiv : the preprint server for health sciences
Published: October 03, 2025
Last Updated: 09/26/2026